Table 1 Clinical characteristics by brain metastasis.
Total (%), N = 553 | With brain metastasis, N = 211 | Without brain metastasis, N = 342 | p value | |
|---|---|---|---|---|
Age | ||||
Mean ± SD | 66.8 ± 11.9 | 66.0 ± 11.5 | 67.2 ± 12.1 | 0.220 |
≥ 65 years old | 312 (56.4) | 117 (55.5) | 195 (57.0) | 0.725 |
ECOG PS | ||||
0–1 | 459 (83.0) | 165 (78.2) | 294 (86.0) | 0.020 |
≥ 2 | 94 (17.0) | 46 (21.8) | 48 (14.0) | |
Sex | ||||
Male | 212 (38.3) | 75 (35.5) | 137 (40.1) | 0.322 |
Female | 341 (61.7) | 136 (64.5) | 205 (59.9) | |
Smoking history | ||||
Current/ex-smoker | 127 (23.0) | 50 (23.7) | 77 (22.5) | 0.756 |
Never smoker | 426 (77.0) | 161 (76.3) | 265 (77.5) | |
Histology | ||||
Adenocarcinoma | 545 (98.6) | 209 (99.1) | 336 (98.2) | 0.717 |
Others | 8 (1.4) | 2 (0.9) | 6 (1.8) | |
EGFR mutation | ||||
L858R | 296 (53.5) | 117 (55.5) | 179 (52.3) | 0.484 |
19 deletion | 257 (46.5) | 94 (44.5) | 163 (47.7) | |
EGFR-TKI | ||||
Gefitinib/erlotinib | 243 (43.9) | 113 (53.6) | 130 (38.0) | < 0.001 |
Afatinib | 310 (56.1) | 98 (46.4) | 212 (62.0) | |
Liver metastasis | ||||
Presence | 69 (12.5) | 36 (17.1) | 33 (9.6) | 0.012 |
Absence | 484 (87.5) | 175 (82.9) | 309 (90.4) | |
